A team of researchers at the Jules Stein Eye Institute and other of their counterparts in the USA, have found that the rosiglitazone (Avandia) treated diabetes patients are less likely to develop proliferative diabetic retinopathy. The researchers have tested the records of nearly 124 patients treated with rosiglitazone and compared them with records of 158 patients with diabetes not treated with the thiazolidinedione.
At the end of the study, the researchers have found that the severe nonproliferative diabetic retinopathy was present in 14 eyes of patients taking rosiglitazone (6.4%) and 24 eyes of patients in the control group (9.3%). After one year, 7.7% of patients taking rosiglitazone progressed to proliferating diabetic retinopathy compared with 29.2% of patients in the control group. After three years, the number of patients who progressed was even greater — 19.2% taking rosiglitazone vs. 47.4% in the control group. Thus, the researchers reported a 59.5% relative risk reduction among patients taking rosiglitazone.
As the reason behind the result, the researchers have found that rosiglitazone may delay progression of retinopathy and preserve vision by reducing the formation of angiogenesis. However the researchers did not prescribe the rosiglitazone to reduce ophthalmic complications. As the researchers say, they need more research on the same subject.
Source: Endocrine Today